Fricke Christopher, Duesmann Charlotte, Woost Timo B, von Hofen-Hohloch Judith, Rumpf Jost-Julian, Weise David, Classen Joseph
Department of Neurology, University of Leipzig, Leipzig, Germany.
Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Front Neurol. 2019 Mar 7;10:174. doi: 10.3389/fneur.2019.00174. eCollection 2019.
Abnormal oscillatory activity in the subthalamic nucleus (STN) may be relevant for motor symptoms in Parkinson's disease (PD). Apart from deep brain stimulation, transcranial magnetic stimulation (TMS) may be suitable for altering these oscillations. We speculated that TMS to different cortical areas (primary motor cortex, M1, and dorsal premotor cortex, PMd) may activate neuronal subpopulations within the STN via corticofugal neurons projecting directly to the nucleus. We hypothesized that PD symptoms can be ameliorated by a lasting decoupling of STN neurons by associative dual-site repetitive TMS (rTMS). Associative dual-site rTMS (1 Hz) directed to PMd and M1 ("ADS-rTMS") was employed in 20 PD patients treated in a blinded, placebo-controlled cross-over design. Results: No adverse events were noted. We found no significant improvement in clinical outcome parameters (videography of MDS-UPDRS-III, finger tapping, spectral tremor power). Variation of the premotor stimulation site did not induce beneficial effects either. A single session of ADS-rTMS was tolerated well, but did not produce a clinically meaningful benefit on Parkinsonian motor symptoms. Successful treatment using TMS targeting subcortical nuclei may require an intervention over several days or more detailed physiological information about the individual brain state and stimulation-induced subcortical effects.
丘脑底核(STN)的异常振荡活动可能与帕金森病(PD)的运动症状有关。除了深部脑刺激外,经颅磁刺激(TMS)可能适合改变这些振荡。我们推测,对不同皮质区域(初级运动皮层,M1,和背侧运动前皮层,PMd)进行TMS可能通过直接投射到该核的皮质离心神经元激活STN内的神经元亚群。我们假设,通过联合双位点重复TMS(rTMS)使STN神经元持久去耦联可以改善PD症状。在一项双盲、安慰剂对照的交叉设计中,对20例PD患者采用了针对PMd和M1的联合双位点rTMS(1Hz)(“ADS-rTMS”)。结果:未观察到不良事件。我们发现临床结局参数(MDS-UPDRS-III录像、手指敲击、频谱震颤功率)没有显著改善。运动前刺激部位的变化也未产生有益效果。单次ADS-rTMS治疗耐受性良好,但对帕金森运动症状未产生临床意义上的益处。使用TMS靶向皮质下核进行成功治疗可能需要数天的干预或有关个体脑状态和刺激诱导的皮质下效应的更详细生理信息。